UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K
                                 CURRENT REPORT
       Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934

       Date of Report (date of earliest event reported): November 16, 2005

                         Advanced Medical Institute Inc.
               (Exact name of registrant as specified in charter)

                                     Nevada
                 (State or other jurisdiction of incorporation)

       000-29531                                          88-0409144
------------------------                       ---------------------------------
(Commission File Number)                       (IRS Employer Identification No.)

                          Level 1, 204-218 Botany Road
                               Alexandria NSW 2015
                                    Australia
              -----------------------------------------------------
              (Address of principal executive offices and zip code)

                                (61) 2 9640 5253
              -----------------------------------------------------
               (Registrant's telephone number including area code)

Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing  obligation  of  registrant  under any of the
following provisions:

[_]   Written communications pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

[_]   Soliciting  material pursuant to Rule 14a-12(b) under the Exchange Act (17
      CFR 240.14a-12(b))

[_]   Pre-commencement  communications  pursuant  to  Rule  14d-2(b)  under  the
      Exchange Act (17 CFR 240.14d-2(b))

[_]   Pre-commencement  communications  pursuant  to  Rule  13e-4(c)  under  the
      Exchange Act (17 CFR 240.13e-4(c))

<PAGE>

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
--------------------------------------------------------------------------------

Information  included  in this Form 8-K may contain  forward-looking  statements
within the meaning of Section 27A of the  Securities  Act and Section 21E of the
Securities  Exchange  Act  of  1934,  as  amended  (the  "Exchange  Act").  This
information may involve known and unknown risks, uncertainties and other factors
which may cause the actual  results,  performance  or  achievements  of Advanced
Medical  Institute Inc. (the  "Company") to be materially  different from future
results, performance or achievements expressed or implied by any forward-looking
statements.  Forward-looking statements,  which involve assumptions and describe
the  Company's  future  plans,   strategies  and  expectations,   are  generally
identifiable   by  use  of  the  words  "may,"   "will,"   "should,"   "expect,"
"anticipate,"  "estimate,"  "believe,"  "intend" or "project" or the negative of
these words or other variations on these words or comparable terminology.  These
forward-looking  statements are based on assumptions that may be incorrect,  and
there  can  be  no   assurance   that  these   projections   included  in  these
forward-looking statements will come to pass. The Company's actual results could
differ  materially  from  those  expressed  or  implied  by the  forward-looking
statements  as a result of various  factors.  Except as required  by  applicable
laws,   the  Company   undertakes   no   obligation   to  update   publicly  any
forward-looking  statements  for any  reason,  even if new  information  becomes
available or other events occur in the future.

Item 1.01 Entry into a Material Definitive Agreement.

On November 16, 2005, Advanced Medical Institute Inc. (the "Registrant") entered
into a Share Exchange Agreement (the "Exchange Agreement") with PE Patent Holdco
Pty Limited (ACN 116 786 737), a privately owned Australian  company ("PE"), and
PE's  shareholders  (the  "Shareholders"),  pursuant  to  which  the  Registrant
acquired all of the issued and outstanding shares of stock of PE in exchange for
the issuance in the aggregate of 5,000,000 of the Registrant's  shares of common
stock (the "Shares") to the Shareholders.  As a result, PE became a wholly-owned
subsidiary of the Registrant.

The purchase  price for 100% of PE is an  aggregate  of 5 million  shares of the
Registrant's common stock valued at $1.10 per share.

Since August 1, 2003,  AMI  Australia  has used in its  business  certain of the
intellectual  property consisting solely of an Australian  innovation patent for
its  premature  ejaculation  programs  (which patent is due to expire on July 9,
2012) and an Australian standard patent application  (Australian standard patent
application No. 2004222783).  Provisional applications for the patents were made
by Dr. Jack Vaisman, the Chief Executive Officer,  President and Chairman of the
Board of Directors of the Company and the Founder, President and Chief Executive
Officer of AMI Australia,  on July 11, 2003 with final patent applications being
made on March 2, 2005 and July 9, 2004 respectively.  The Australian  innovation
patent was issued to Dr Vaisman on July 2, 2005 who on October 28, 2005 assigned
the patent to PE in exchange for 1,249,999 shares of PE. Since October 28, 2005,
the patents have been orally licensed by AMI Australia from PE Patent Holdco Pty
Limited on a short-term  royalty free  arrangement.  Dr.  Vaisman sold 1,250,000
shares of PE (100% of his  shares)  on  October  31,  2005 for an  aggregate  of
$500,000. Until November 14, 2005, Dr. Vaisman served as the sole director of PE
when he resigned and Igor Chalik was appointed as director in his place.

The  development  of  the  intellectual  property  underlying  the  patents  was
undertaken and funded by Dr. Vaisman.  The innovation patent,  titled "Treatment
of Premature  Ejaculation"  relates to various methods of treatment delivery via
nasal (mucosal) inhalation and topical application of certain formulations which
are used in AMI Australia's  treatment programs for premature  ejaculation.  The
patents and associated  formulations  are integral to AMI Australia's  premature
ejaculation treatment programs.  AMI Australia's  injection,  lozenge and tablet
impotence and erectile dysfunction treatment programs are not patent protected.


                                        2
<PAGE>

In acquiring PE, the  Registrant  acquires only the right to use the Patents and
the associated pharmaceutical  formulations,  treatment methodologies and dosing
manuals  in  Australia  and  has no  rights  to use  the  Patents  or any of the
underlying  intellectual property in any other country.  Nether Dr. Vaisman, nor
any other  director or officer of the  Registrant,  AMI  Australia or any of the
Registrant's  subsidiaries  (other than in their capacities with the Registrant)
has or will benefit directly or indirectly from the Registrant's purchase of PE.
PE's assets include the Patents and the right to use and/or  licence/sub-licence
the associated pharmaceutical  formulations,  treatment methodologies and dosing
manuals in Australia.

As a result of the  acquisition of PE, the  Registrant  will own the Patents and
all of  the  rights  to  utilize  the  protected  technologies  and  methods  in
Australia.  The Patents are  currently  utilized by AMI Australia in relation to
its premature  ejaculation treatment programs in Australia under an oral license
with PE. The Patents relate to various  methods of treatment  delivery via nasal
(mucosal)   inhalation  and  topical   application  of  certain   pharmaceutical
formulations which are used in AMI Australia's  treatment programs for premature
ejaculation.  These  formulations  have  previously been used to treat premature
ejaculation  and other  medical  conditions.  PE currently  has a  royalty-free,
at-will license arrangement with AMI Australia to permit use the Patents.  Under
the agreement, the license arrangement may be ended at any time by either party.
Acquisition  of the Patents will give the Registrant  and its  subsidiaries  the
exclusive  right to exploit the Patents and associated  technology in connection
with the  provision of  premature  ejaculation  treatment  programs in Australia
during the term of the Patents and will  obviate any future  obligation  for the
Registrant or any of its  subsidiaries to pay royalties to a third party for use
of the Patents.

The  Innovation  Patent  expires  on July 9,  2012  and,  assuming  a grant of a
standard  patent is obtained,  the standard  patent will expire on July 9, 2024.
Innovation  Patents are unique to  Australia,  they provide a shorter  length of
protection  than  standard  patents and are approved  more quickly than standard
patent  applications but they are otherwise  equivalent to a standard Australian
patent.  The grant of the standard  patent will extend the period of  protection
available to PE already available under the Innovation Patent.

AMI Australia commissioned PKF Corporate Advisers Pty Limited ("PKF") to perform
an  independent  valuation  of the  Patents  in  connection  with  the  proposed
acquisition  of PE and the Board of Directors of the  Registrant  has determined
that the  acquisition  price  represents  a 10%  premium to the  midpoint of the
independent valuation provided by PKF.

The description of the transactions  contemplated by the Exchange  Agreement set
forth herein does not purport to be complete and is qualified in its entirety by
reference  to  the  full  text  of  each  of the  exhibits  filed  herewith  and
incorporated by this reference.

The information in this Report, including the exhibit, shall not be deemed to be
"filed" for the purposes of Section 18 of the  Securities  Exchange Act of 1934,
as amended,  or otherwise  subject to the liabilities of that Section.  It shall
not be deemed  incorporated  by reference in any filing under the Securities Act
of 1933,  as  amended,  except  as  shall be  expressly  set  forth by  specific
reference in such a filing.


                                        3
<PAGE>

Item 9.01 Financial Statements and Exhibits.

      (b) Pro forma  financial  statements will be provided by amendment to this
8-K not later than 74 calendar days after the date of this initial report.

      (c) Exhibits.
          --------
       Exhibit No.       Description

       2.2               Share Exchange Agreement dated as of November 16, 2005.

       99.1              Press Release dated November 17, 2005.


                                        4
<PAGE>

                                   SIGNATURES

      Pursuant to the  requirements of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                        ADVANCED MEDICAL INSTITUTE INC.


                                       By:  /s/ Dilip Shrestha
                                            ------------------------------------
                                        Name:  Dilip Shrestha
                                        Title: Chief Financial Officer

Dated:  November 17, 2005


                                        5
<PAGE>

                                  EXHIBIT INDEX

       Exhibit No.       Description

       2.2               Share Exchange Agreement dated as of November 16, 2005.

       99.1              Press Release dated November 17, 2005.


                                        6
{"company-data": {"conformed-name": "ADVANCED MEDICAL INSTITUTE INC.", "cik": "0001096620", "assigned-sic": "8090", "irs-number": "880409144", "state-of-incorporation": "NV", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-29531", "film-number": "051211594"}, "business-address": {"street1": "C/O ADVANCED MEDICAL INSTITUTE INC.", "street2": "LEVEL 1 204-218 BOTANY ROAD", "city": "ALEXANDRIA", "state": "C3", "zip": "NSW 2015", "phone": "61 2 9640 5253"}, "mail-address": {"street1": "C/O ADVANCED MEDICAL INSTITUTE INC.", "street2": "LEVEL 1 204-218 BOTANY ROAD", "city": "ALEXANDRIA", "state": "C3", "zip": "NSW 2015"}, "former-company": {"former-conformed-name": "HAWKSDALE FINANCIAL VISIONS INC", "date-changed": "19991012"}}
UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K
                                 CURRENT REPORT
       Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934

       Date of Report (date of earliest event reported): November 16, 2005

                         Advanced Medical Institute Inc.
               (Exact name of registrant as specified in charter)

                                     Nevada
                 (State or other jurisdiction of incorporation)

       000-29531                                          88-0409144
------------------------                       ---------------------------------
(Commission File Number)                       (IRS Employer Identification No.)

                          Level 1, 204-218 Botany Road
                               Alexandria NSW 2015
                                    Australia
              -----------------------------------------------------
              (Address of principal executive offices and zip code)

                                (61) 2 9640 5253
              -----------------------------------------------------
               (Registrant's telephone number including area code)

Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing  obligation  of  registrant  under any of the
following provisions:

[_]   Written communications pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

[_]   Soliciting  material pursuant to Rule 14a-12(b) under the Exchange Act (17
      CFR 240.14a-12(b))

[_]   Pre-commencement  communications  pursuant  to  Rule  14d-2(b)  under  the
      Exchange Act (17 CFR 240.14d-2(b))

[_]   Pre-commencement  communications  pursuant  to  Rule  13e-4(c)  under  the
      Exchange Act (17 CFR 240.13e-4(c))
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
--------------------------------------------------------------------------------

Information  included  in this Form 8-K may contain  forward-looking  statements
within the meaning of Section 27A of the  Securities  Act and Section 21E of the
Securities  Exchange  Act  of  1934,  as  amended  (the  "Exchange  Act").  This
information may involve known and unknown risks, uncertainties and other factors
which may cause the actual  results,  performance  or  achievements  of Advanced
Medical  Institute Inc. (the  "Company") to be materially  different from future
results, performance or achievements expressed or implied by any forward-looking
statements.  Forward-looking statements,  which involve assumptions and describe
the  Company's  future  plans,   strategies  and  expectations,   are  generally
identifiable   by  use  of  the  words  "may,"   "will,"   "should,"   "expect,"
"anticipate,"  "estimate,"  "believe,"  "intend" or "project" or the negative of
these words or other variations on these words or comparable terminology.  These
forward-looking  statements are based on assumptions that may be incorrect,  and
there  can  be  no   assurance   that  these   projections   included  in  these
forward-looking statements will come to pass. The Company's actual results could
differ  materially  from  those  expressed  or  implied  by the  forward-looking
statements  as a result of various  factors.  Except as required  by  applicable
laws,   the  Company   undertakes   no   obligation   to  update   publicly  any
forward-looking  statements  for any  reason,  even if new  information  becomes
available or other events occur in the future.

Item 1.01 Entry into a Material Definitive Agreement.

On November 16, 2005, Advanced Medical Institute Inc. (the "Registrant") entered
into a Share Exchange Agreement (the "Exchange Agreement") with PE Patent Holdco
Pty Limited (ACN 116 786 737), a privately owned Australian  company ("PE"), and
PE's  shareholders  (the  "Shareholders"),  pursuant  to  which  the  Registrant
acquired all of the issued and outstanding shares of stock of PE in exchange for
the issuance in the aggregate of 5,000,000 of the Registrant's  shares of common
stock (the "Shares") to the Shareholders.  As a result, PE became a wholly-owned
subsidiary of the Registrant.

The purchase  price for 100% of PE is an  aggregate  of 5 million  shares of the
Registrant's common stock valued at $1.10 per share.

Since August 1, 2003,  AMI  Australia  has used in its  business  certain of the
intellectual  property consisting solely of an Australian  innovation patent for
its  premature  ejaculation  programs  (which patent is due to expire on July 9,
2012) and an Australian standard patent application  (Australian standard patent
application No. 2004222783).  Provisional applications for the patents were made
by Dr. Jack Vaisman, the Chief Executive Officer,  President and Chairman of the
Board of Directors of the Company and the Founder, President and Chief Executive
Officer of AMI Australia,  on July 11, 2003 with final patent applications being
made on March 2, 2005 and July 9, 2004 respectively.  The Australian  innovation
patent was issued to Dr Vaisman on July 2, 2005 who on October 28, 2005 assigned
the patent to PE in exchange for 1,249,999 shares of PE. Since October 28, 2005,
the patents have been orally licensed by AMI Australia from PE Patent Holdco Pty
Limited on a short-term  royalty free  arrangement.  Dr.  Vaisman sold 1,250,000
shares of PE (100% of his  shares)  on  October  31,  2005 for an  aggregate  of
$500,000. Until November 14, 2005, Dr. Vaisman served as the sole director of PE
when he resigned and Igor Chalik was appointed as director in his place.

The  development  of  the  intellectual  property  underlying  the  patents  was
undertaken and funded by Dr. Vaisman.  The innovation patent,  titled "Treatment
of Premature  Ejaculation"  relates to various methods of treatment delivery via
nasal (mucosal) inhalation and topical application of certain formulations which
are used in AMI Australia's  treatment programs for premature  ejaculation.  The
patents and associated  formulations  are integral to AMI Australia's  premature
ejaculation treatment programs.  AMI Australia's  injection,  lozenge and tablet
impotence and erectile dysfunction treatment programs are not patent protected.

                                        2
In acquiring PE, the  Registrant  acquires only the right to use the Patents and
the associated pharmaceutical  formulations,  treatment methodologies and dosing
manuals  in  Australia  and  has no  rights  to use  the  Patents  or any of the
underlying  intellectual property in any other country.  Nether Dr. Vaisman, nor
any other  director or officer of the  Registrant,  AMI  Australia or any of the
Registrant's  subsidiaries  (other than in their capacities with the Registrant)
has or will benefit directly or indirectly from the Registrant's purchase of PE.
PE's assets include the Patents and the right to use and/or  licence/sub-licence
the associated pharmaceutical  formulations,  treatment methodologies and dosing
manuals in Australia.

As a result of the  acquisition of PE, the  Registrant  will own the Patents and
all of  the  rights  to  utilize  the  protected  technologies  and  methods  in
Australia.  The Patents are  currently  utilized by AMI Australia in relation to
its premature  ejaculation treatment programs in Australia under an oral license
with PE. The Patents relate to various  methods of treatment  delivery via nasal
(mucosal)   inhalation  and  topical   application  of  certain   pharmaceutical
formulations which are used in AMI Australia's  treatment programs for premature
ejaculation.  These  formulations  have  previously been used to treat premature
ejaculation  and other  medical  conditions.  PE currently  has a  royalty-free,
at-will license arrangement with AMI Australia to permit use the Patents.  Under
the agreement, the license arrangement may be ended at any time by either party.
Acquisition  of the Patents will give the Registrant  and its  subsidiaries  the
exclusive  right to exploit the Patents and associated  technology in connection
with the  provision of  premature  ejaculation  treatment  programs in Australia
during the term of the Patents and will  obviate any future  obligation  for the
Registrant or any of its  subsidiaries to pay royalties to a third party for use
of the Patents.

The  Innovation  Patent  expires  on July 9,  2012  and,  assuming  a grant of a
standard  patent is obtained,  the standard  patent will expire on July 9, 2024.
Innovation  Patents are unique to  Australia,  they provide a shorter  length of
protection  than  standard  patents and are approved  more quickly than standard
patent  applications but they are otherwise  equivalent to a standard Australian
patent.  The grant of the standard  patent will extend the period of  protection
available to PE already available under the Innovation Patent.

AMI Australia commissioned PKF Corporate Advisers Pty Limited ("PKF") to perform
an  independent  valuation  of the  Patents  in  connection  with  the  proposed
acquisition  of PE and the Board of Directors of the  Registrant  has determined
that the  acquisition  price  represents  a 10%  premium to the  midpoint of the
independent valuation provided by PKF.

The description of the transactions  contemplated by the Exchange  Agreement set
forth herein does not purport to be complete and is qualified in its entirety by
reference  to  the  full  text  of  each  of the  exhibits  filed  herewith  and
incorporated by this reference.

The information in this Report, including the exhibit, shall not be deemed to be
"filed" for the purposes of Section 18 of the  Securities  Exchange Act of 1934,
as amended,  or otherwise  subject to the liabilities of that Section.  It shall
not be deemed  incorporated  by reference in any filing under the Securities Act
of 1933,  as  amended,  except  as  shall be  expressly  set  forth by  specific
reference in such a filing.

                                        3
Item 9.01 Financial Statements and Exhibits.

      (b) Pro forma  financial  statements will be provided by amendment to this
8-K not later than 74 calendar days after the date of this initial report.

      (c) Exhibits.
          --------
       Exhibit No.       Description

       2.2               Share Exchange Agreement dated as of November 16, 2005.

       99.1              Press Release dated November 17, 2005.

                                        4
SIGNATURES

      Pursuant to the  requirements of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                        ADVANCED MEDICAL INSTITUTE INC.

                                       By:  /s/ Dilip Shrestha
                                            ------------------------------------
                                        Name:  Dilip Shrestha
                                        Title: Chief Financial Officer

Dated:  November 17, 2005

                                        5
EXHIBIT INDEX

       Exhibit No.       Description

       2.2               Share Exchange Agreement dated as of November 16, 2005.

       99.1              Press Release dated November 17, 2005.

                                        6